Abstract
Active inflammatory bowel disease (IBD), combined immunosuppression and corticosteroid therapy have all been identified as risk factors for a poor outcome in COVID-19 infection. The management of patients with both COVID-19 infection and active IBD is therefore complex. We present the case of a 31-year-old patient with Crohn’s disease, on dual immunosuppression with infliximab and mercaptopurine presenting with inflammatory small bowel obstruction and COVID-19 infection. The case highlights the use of nutritional therapy, which remains underused in the management of adults with IBD, to manage his flare acutely. Following negative SARS-CoV-2 PCR testing and SARS-CoV-2 IgG testing confirming an antibody response, ustekinumab (anti-interleukin 12/23) was prescribed for long-term maintenance.
Keywords: Crohn’s disease; inflammatory bowel disease.
【저자키워드】 Inflammatory bowel disease, Crohn's disease, 【초록키워드】 therapy, Antibody Response, Immunosuppression, outcome, risk factor, Inflammatory bowel disease, COVID-19 infection, management, Patient, disease, SARS-CoV-2 IgG, IBD, Inflammatory, SARS-CoV-2 PCR testing, complex, corticosteroid therapy, bowel, highlight, presenting, 【제목키워드】 therapy, Immunosuppression, disease, Crohn's disease, Immunosuppressed,